Positive News Coverage Somewhat Unlikely to Impact TRACON Pharmaceuticals (TCON) Share Price
News stories about TRACON Pharmaceuticals (NASDAQ:TCON) have trended positive on Tuesday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TRACON Pharmaceuticals earned a coverage optimism score of 0.29 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 47.2652237850477 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- 34 Stocks Moving In Tuesday’s Pre-Market Session – Benzinga (benzinga.com)
- 8 Stocks To Watch For November 14, 2017 | Benzinga – Benzinga (benzinga.com)
- FDA Nod For AGN, ZYME Strikes A Deal With Janssen Biotech, TCON Abuzz – Nasdaq (nasdaq.com)
- Overall response rate of 24% seen with no dose limiting toxicity observed (globenewswire.com)
- TRACON Pharmaceuticals Announces Positive Results from Phase 1 Trial of TRC102 and Fludara® in Patients with Advanced Hematologic Malignancy Published in Oncotarget (finance.yahoo.com)
TRACON Pharmaceuticals (NASDAQ TCON) remained flat at $$2.80 during mid-day trading on Tuesday. The company had a trading volume of 300,100 shares, compared to its average volume of 98,149. TRACON Pharmaceuticals has a fifty-two week low of $2.00 and a fifty-two week high of $7.30. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.80 and a current ratio of 3.80.
TRACON Pharmaceuticals (NASDAQ:TCON) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.32. The firm had revenue of $7.50 million during the quarter, compared to analysts’ expectations of $7.60 million. TRACON Pharmaceuticals had a negative return on equity of 83.43% and a negative net margin of 201.21%. analysts forecast that TRACON Pharmaceuticals will post -1.21 EPS for the current year.
Separately, Zacks Investment Research cut TRACON Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th.
WARNING: This article was first reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/11/14/positive-news-coverage-somewhat-unlikely-to-impact-tracon-pharmaceuticals-tcon-share-price.html.
About TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).
Receive News & Ratings for TRACON Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.